Augmentin Dosing Guidelines for Respiratory Infections

Adult Dosing

The American Academy of Otolaryngology-Head and Neck Surgery recommends dosing Augmentin at 875 mg/125 mg every 12 hours or 500 mg/125 mg every 8 hours for 7-10 days for mild infections in adults who have not received antibiotics in the previous 4-6 weeks 1, 2
The European Respiratory Society recommends a duration of 7-10 days for most respiratory infections in adults 3

For children under 3 years, the European Society of Clinical Microbiology and Infectious Diseases recommends 80-100 mg/kg/day of amoxicillin component in three divided doses for pneumonia and lower respiratory infections 4, 5
For children 3-5 years, amoxicillin-clavulanate (80 mg/kg/day amoxicillin component) is justified when there is insufficient vaccination against H. influenzae type b or coexistence of purulent acute otitis media 5, 6, 7

For acute bacterial rhinosinusitis, the American Academy of Otolaryngology-Head and Neck Surgery recommends 875 mg/125 mg every 12 hours or 500 mg/125 mg every 8 hours for adults 1, 2
For community-acquired pneumonia, the European Respiratory Society recommends 875 mg/125 mg every 12 hours or 500 mg/125 mg every 8 hours for adults 3
For community-acquired pneumonia in children, the European Society of Clinical Microbiology and Infectious Diseases recommends 80-100 mg/kg/day of amoxicillin component in three divided doses 4, 5

The European Society of Clinical Microbiology and Infectious Diseases and the American Academy of Otolaryngology-Head and Neck Surgery recommend evaluating therapeutic efficacy after 2-3 days of treatment and considering alternative antibiotics or reevaluation if no improvement is observed 2, 4
The American Academy of Otolaryngology-Head and Neck Surgery recommends considering alternative antibiotics in patients with immediate Type I hypersensitivity reactions to beta-lactams, though bacterial failure rates of 20-25% are possible with non-beta-lactam alternatives 1

The American College of Physicians and Infectious Diseases Society of America recommends amoxicillin-clavulanate for empiric treatment of bacterial superinfection following influenza to provide activity against S. pneumoniae, Staphylococcus aureus, and H. influenzae, with a strength of evidence rated as high 8, 9
The European Society of Clinical Microbiology and Infectious Diseases suggests that amoxicillin-clavulanate provides broader spectrum coverage than amoxicillin alone for adults with risk factors, addressing beta-lactamase-producing H. influenzae and penicillin-resistant S. pneumoniae, based on moderate-quality evidence 10

The Pediatric Infectious Diseases Society recommends high-dose amoxicillin-clavulanate as a second-line agent for children under 3 years with non-severe pneumonia when first-line amoxicillin fails or when enhanced coverage against beta-lactamase-producing H. influenzae and resistant S. pneumoniae is needed, with a strength of evidence rated as moderate 11, 12
The same society also recommends amoxicillin-clavulanate for children 3-5 years when there is insufficient vaccination against H. influenzae type b or coexisting purulent acute otitis media, although the evidence quality is lower 11, 12

The Infectious Diseases Society of America advises against using amoxicillin-clavulanate for atypical pneumonia caused by Mycoplasma pneumoniae or Chlamydophila pneumoniae, instead recommending a macrolide or respiratory fluoroquinolone, based on high-quality evidence 11, 12
The European Respiratory Society suggests that if no improvement occurs within 72 hours of initiating treatment, clinical and radiological reassessment should be considered, and hospitalization may be necessary for complications, with a strength of evidence rated as moderate 10

The European Respiratory Society, British Thoracic Society, and French guidelines recommend amoxicillin-clavulanate as first-line or second-line therapy for pneumonia, due to its superior coverage of key pathogens, including beta-lactamase-producing organisms and resistant Streptococcus pneumoniae 13, 14, 15
The French guidelines specifically recommend amoxicillin-clavulanate for broader spectrum coverage when S. pneumoniae with decreased penicillin susceptibility is a concern, with a strength of evidence rated as high 13
The British Thoracic Society guidelines recommend combination therapy with amoxicillin-clavulanate or second-generation cephalosporins plus macrolides for hospitalized patients with non-severe pneumonia, based on moderate-quality evidence 14, 15

Amoxicillin-clavulanate provides superior activity against beta-lactamase-producing Haemophilus influenzae, Moraxella catarrhalis, and penicillin-resistant S. pneumoniae, with a high level of evidence supporting its use 16
Cefpodoxime shows less predictable activity against resistant S. pneumoniae compared to high-dose amoxicillin-clavulanate, based on low-quality evidence 16

The American Thoracic Society and Infectious Diseases Society of America recommend amoxicillin-clavulanate as a preferred agent for empiric therapy in patients with community-acquired pneumonia, due to its high efficacy and safety profile 16, 17
Cefpodoxime is not included in most major pneumonia guidelines as a preferred agent, due to limited clinical trial data supporting its use, with a low strength of evidence 16, 17, 14

The American Academy of Pediatrics recommends amoxicillin-clavulanate for children under 3 years with pneumonia, due to its high efficacy and safety profile, with a high level of evidence supporting its use 13
Children over 3 years may require macrolide addition to beta-lactam therapy due to the increased prevalence of atypical bacteria, based on moderate-quality evidence 13

Adults with comorbidities require broader spectrum coverage with amoxicillin-clavulanate, due to its high efficacy and safety profile, with a high level of evidence supporting its use 16, 17
The Infectious Diseases Society of America recommends avoiding the use of cephalosporins as monotherapy when atypical pneumonia is suspected, due to limited clinical trial data supporting their use, with a low strength of evidence 13, 16

The British Thoracic Society recommends evaluating therapeutic efficacy after 48-72 hours of treatment, with a moderate level of evidence supporting this approach 14, 15
If no improvement by 72 hours, consider clinical and radiological reassessment, possible hospitalization, or switch to respiratory fluoroquinolone, based on low-quality evidence 14, 15